METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Clinical trials for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could drug holidays ease prostate cancer treatment fatigue?
Disease control Recruiting nowThis study looks at whether men with metastatic hormone-sensitive prostate cancer who have a very good response to initial therapy can safely take breaks from their hormone-blocking medication. The goal is to see if this approach reduces fatigue and other side effects while still…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated May 26, 2026 03:15 UTC
-
New hope for prostate cancer: adding local treatment to drug therapy may delay progression
Disease control Recruiting nowThis study is for men with metastatic hormone-sensitive prostate cancer that has spread to a limited number of sites. It compares standard drug therapy (apalutamide plus hormone therapy) to the same drugs plus a local treatment like radiation or surgery to the prostate. The goal …
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: NA • Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New prostate cancer combo aims to outperform standard therapy
Disease control Recruiting nowThis phase 3 study tests whether a new drug called rezvilutamide, combined with hormone therapy, works better than the current standard enzalutamide plus hormone therapy for men with low-volume metastatic hormone-sensitive prostate cancer. About 206 participants will receive one …
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New combo therapy targets advanced prostate cancer in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called xaluritamig combined with standard hormone therapies (darolutamide or abiraterone) in 60 men whose prostate cancer has spread but still responds to hormone treatment. The main goal is to check safety and side effects, while also look…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New combo therapy aims to control advanced prostate cancer
Disease control Recruiting nowThis study tests a new drug called tulmimetostat combined with standard hormone therapies (darolutamide or abiraterone) in men whose prostate cancer has spread but still responds to hormone treatment. The goal is to see if the combination is safe and works better than standard ca…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 18, 2026 12:00 UTC
-
New study tracks hidden side effects of prostate cancer drugs
Knowledge-focused Recruiting nowThis study follows 102 men with advanced prostate cancer to see how their thinking, energy, mood, and sleep change during standard treatment. Participants will fill out questionnaires at the start, 3 months, and 6 months. The goal is to better understand the real-world impact of …
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: Ankara Etlik City Hospital • Aim: Knowledge-focused
Last updated May 26, 2026 03:10 UTC
-
5,000 men with advanced prostate cancer to be tracked in major new registry study
Knowledge-focused Recruiting nowThis study is a registry that will follow 5,000 men with prostate cancer that has come back or spread. The goal is to see what treatments doctors actually use and how the disease progresses over time. Participants are grouped by their cancer stage, from early PSA recurrence to ad…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: UroTrials Company (GmbH) • Aim: Knowledge-focused
Last updated May 22, 2026 13:52 UTC
-
New study tracks darolutamide combo in men with Low-Volume prostate cancer
Knowledge-focused Recruiting nowThis observational study looks at Japanese men with low-volume metastatic hormone-sensitive prostate cancer (mHSPC) who are taking darolutamide along with standard hormone therapy and chemotherapy. The goal is to see how safe the combination is and how well it works in everyday m…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: Bayer • Aim: Knowledge-focused
Last updated May 22, 2026 13:50 UTC